Greenwood, IN, United States of America

Adam Joseph Kreuzman


Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 41(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1996)
  • Greenwood, IN (US) (1999 - 2005)

Company Filing History:


Years Active: 1996-2005

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Adam Joseph Kreuzman

Introduction

Adam Joseph Kreuzman is a notable inventor based in Greenwood, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel antibiotics. With a total of 3 patents to his name, Kreuzman is recognized for his innovative approaches to combating bacterial infections.

Latest Patents

Kreuzman's latest patents include groundbreaking work on lipoglycopeptide antibiotics. These novel lipoglycopeptides exhibit bacterial signal peptidase inhibitory activity, providing a new avenue for treating bacterial infections. The invention also encompasses actinomycete strains that produce these lipoglycopeptides, methods for culturing these strains, and pharmaceutical compositions that utilize these compounds. This innovation holds promise for both human and veterinary medicine.

Another significant patent by Kreuzman is related to the deacylation process of teicoplanin. This invention focuses on deacyl teicoplanin and outlines a process for preparing it by reacting teicoplanin with ECB deacylase. The resulting deacyl teicoplanin can be further alkylated to produce compounds that are useful for their antibacterial activity.

Career Highlights

Kreuzman is currently employed at Eli Lilly and Company, where he continues to advance his research in pharmaceuticals. His work has been instrumental in developing new treatments that address pressing health concerns related to bacterial infections.

Collaborations

Throughout his career, Kreuzman has collaborated with esteemed colleagues, including Wu-Kuang Yeh and Matthew David Belvo. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Adam Joseph Kreuzman exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the development of novel antibiotics, highlight the importance of research and collaboration in addressing global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…